Fundación Jiménez Díaz -ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2019

  1. Clinical impact of circulating tumor RAS and BRAF mutation dynamics in patients with metastatic colorectal cancer treated with first-line chemotherapy plus anti–epidermal growth factor receptor therapy

    JCO Precision Oncology, Vol. 3

2018

  1. Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients

    Neoplasia (United States), Vol. 20, Núm. 7, pp. 678-686

  2. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab

    Oncologist, Vol. 23, Núm. 9, pp. 1092-1102

2017

  1. Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

    British Journal of Cancer, Vol. 117, Núm. 12, pp. 1777-1786

2015

  1. Clinical guideline SEOM: hepatocellular carcinoma

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 988-995

2013

  1. Level of HER2 gene amplification predicts response and overall survival in her2-positive advanced gastric cancer treated with trastuzumab

    Journal of Clinical Oncology, Vol. 31, Núm. 35, pp. 4445-4452